# ARTV catalysts: Artiva Biotherapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/artv/catalysts

> Artiva Biotherapeutics, Inc. (ARTV) has 2 upcoming catalysts. The next is the allogeneic nk cells primary completion, January 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Artiva Biotherapeutics, Inc. |
| Ticker | ARTV (Nasdaq) |
| SEC CIK | 1817241 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/artv |

## Cash runway

Cash $319.1M as of 2026-09-30; quarterly burn $28.4M; about 33.7 months of runway at that rate (XBRL company facts, accession 0001193125-26-453549).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Aug 2023 | [TRUXIMA® (rituximab) trial start](https://sec-api.dev/pdufa/rituximab) | ARTV | class III or IV LN in August 2023 | completed | "6 clinical trial in patients with class III or IV LN in August 2023, and we dosed the first patient in this trial in April 2024." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1817241/000095017025043837/artv-20241231.htm)) |
| November 12, 2024 | [Artiva Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/artv/catalysts) | ARTV |  | completed | "Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817241/000095017024125359/artv-ex99_1.htm)) |
| 1H 2025 | [TRUXIMA® (rituximab) interim data readout](https://sec-api.dev/pdufa/rituximab) | ARTV |  | scheduled | "We expect to report initial data on autoimmune indications from at least one of our Phase 1/1b trial or the basket IIT in the first half of 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1817241/000095017025043837/artv-20241231.htm)) |
| 1H 2025 | [AlloNK (AB-101) interim data readout](https://sec-api.dev/pdufa/ab-101) | ARTV |  | scheduled | "Initial data for AlloNK® in autoimmune indications from the Phase 1/1b trial or the basket IIT expected in the first half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817241/000095017024125359/artv-ex99_1.htm)) |
| March 24, 2025 | [Artiva Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/artv/catalysts) | ARTV |  | completed | "Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817241/000095017025043828/artv-ex99_1.htm)) |
| May 8, 2025 | [Artiva Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/artv/catalysts) | ARTV |  | completed | "Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817241/000095017025066416/artv-ex99_1.htm)) |
| Aug 2025 | [TRUXIMA® (rituximab) trial start](https://sec-api.dev/pdufa/rituximab) | ARTV |  | completed | "In addition, we announced that, following Investigational New Drug application clearance by the U.S. Food and Drug Administration (FDA), we have initiated a global Phase 2a company-sponsored basket clinical trial for AlloNK in combination with rituximab for refractory rheumatoid arthritis (RA), Sjögren's disease, idiopathic inflammatory myopathies and systemic sclerosis, with site initiation and enrollment underway, which we believe is the first company-sponsored trial exploring an allogeneic cell therapy in refractory RA and Sjögren's disease in the U.S. In August 2025, we announced that we treated the first patient in the Phase 2a basket trial." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1817241/000119312526214706/d119010d424b5.htm)) |
| August 6, 2025 | [Artiva Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/artv/catalysts) | ARTV |  | completed | "Artiva Biotherapeutics Reports Second Quarter 2025 Financial Results, Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817241/000095017025104028/artv-ex99_1.htm)) |
| November 12, 2025 | [Artiva Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/artv/catalysts) | ARTV |  | completed | "Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817241/000119312525275867/artv-ex99_1.htm)) |
| March 10, 2026 | [Artiva Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/artv/catalysts) | ARTV |  | completed | "Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817241/000119312526100131/artv-ex99_1.htm)) |
| May 8, 2026 | [AlloNK (AB-101) interim data readout](https://sec-api.dev/pdufa/ab-101) | ARTV | debilitating autoimmune diseases, today | completed, positive | "(Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced positive initial clinical data from ongoing clinical trials evaluating AlloNK® (also known as AB-101) in combination with rituximab." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817241/000119312526213239/d38160dex992.htm)) |
| May 8, 2026 | [TRUXIMA® (rituximab) interim data readout](https://sec-api.dev/pdufa/rituximab) | ARTV |  | completed, positive | "On May 8, 2026, we announced positive initial clinical data from ongoing clinical trials evaluating AlloNK in combination with rituximab." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1817241/000119312526338029/artv-20260630.htm)) |
| May 8, 2026 | [Artiva Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/artv/catalysts) | ARTV |  | completed | "Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817241/000119312526213239/d38160dex991.htm)) |
| 2H 2026 | [TRUXIMA® (rituximab) trial start](https://sec-api.dev/pdufa/rituximab) | ARTV |  | scheduled | "The Company expects to initiate the registrational trial in the second half of 2026 and report primary efficacy data in the second half of 2028, with a potential BLA submission in 2029." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1817241/000119312526213239/d38160d8k.htm)) |
| August 6, 2026 | [Artiva Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/artv/catalysts) | ARTV |  | completed | "Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817241/000119312526337986/artv-ex99_1.htm)) |
| January 2028 | [Allogeneic nk cells primary completion](https://sec-api.dev/pdufa/allogeneic-nk-cells) | ARTV |  | scheduled | "NCT06991114 (AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Artiva Biotherapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06991114)) |
| Jan to Apr 2028 | [Allogeneic nk cells topline data readout](https://sec-api.dev/pdufa/allogeneic-nk-cells) | ARTV |  | scheduled | "NCT06991114 (AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Artiva Biotherapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06991114)) |

## Drugs

- [AlloNK (AB-101)](https://sec-api.dev/pdufa/ab-101): debilitating autoimmune diseases, today
- [Allogeneic nk cells](https://sec-api.dev/pdufa/allogeneic-nk-cells): Refractory Rheumatoid Arthritis (RA)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/artv/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ARTV catalysts: Artiva Biotherapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/artv/catalysts

```bibtex
@misc{secapidev_companies_artv_catalysts_20261116,
  title        = {ARTV catalysts: Artiva Biotherapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/artv/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_artv_catalysts_20261116","title":"ARTV catalysts: Artiva Biotherapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/artv/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
